ProCE Banner Activity

Applying New Evidence to Optimize Care in Advanced Prostate Cancer

Text Module
Gain expert insights on the latest clinical data informing optimal care of patients with advanced prostate cancer using new therapeutic strategies.

Released: October 08, 2020

Expiration: October 07, 2021

No longer available for credit.

Share

Faculty

Matthew R. Smith

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by University of South Florida
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Bayer Healthcare Pharma

Pfizer TEXT Only

Sanofi Genzyme Corp

Learning Objectives

  • Apply expert recommendations for the sequencing of available and emerging hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies (alone and in combination) to safely and effectively integrate them into the care of patients with metastatic castration-resistant prostate cancer
  • Evaluate new therapeutic options for nonmetastatic castration-resistant prostate cancer
  • Plan optimal, individualized therapeutic strategies for M0 or metastatic hormone-sensitive prostate cancer
  • Assess and manage the risk for cardiotoxicity or bone loss previous to and/or during prostate cancer treatment
  • Refer appropriate patients with prostate cancer to ongoing clinical trials assessing novel therapies alone and in combination throughout the disease continuum to aid in trial enrollment

Faculty Disclosure

Primary Author

Matthew R. Smith, MD, PhD

Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew R. Smith, MD, PhD, has disclosed that he has served on the advisory board and received consulting fees from Amgen, Astellas, Bayer, Janssen, and Lilly, and received funds for research support paid to his institution from Amgen, Arvinas, Bayer, and Janssen, and Lilly.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.